Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS

Connor Clark & Lunn Investment Management Ltd. raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 107.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 265,707 shares of the company’s stock after purchasing an additional 137,604 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.65% of Keros Therapeutics worth $3,547,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in KROS. CWM LLC grew its holdings in Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after buying an additional 2,641 shares in the last quarter. Entropy Technologies LP acquired a new position in Keros Therapeutics in the 1st quarter valued at about $121,000. AlphaQuest LLC grew its stake in shares of Keros Therapeutics by 268.0% in the 1st quarter. AlphaQuest LLC now owns 13,234 shares of the company’s stock valued at $135,000 after buying an additional 9,638 shares during the period. Corebridge Financial Inc. increased its stake in Keros Therapeutics by 6.4% during the first quarter. Corebridge Financial Inc. now owns 16,212 shares of the company’s stock worth $165,000 after acquiring an additional 972 shares during the last quarter. Finally, Covestor Ltd increased its stake in Keros Therapeutics by 1,230.8% during the first quarter. Covestor Ltd now owns 17,061 shares of the company’s stock worth $174,000 after acquiring an additional 15,779 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company lowered their price target on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a research note on Wednesday. Wedbush boosted their price target on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright dropped their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $30.22.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $17.26 on Friday. The stock has a market capitalization of $525.91 million, a P/E ratio of 11.21, a price-to-earnings-growth ratio of 0.38 and a beta of 1.12. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The company has a 50 day moving average price of $15.66 and a 200 day moving average price of $14.73.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.93. The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $4.22 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The company’s quarterly revenue was up 3585.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.41) earnings per share. On average, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.